# Special 510(k) Summary

# Introduction

According to the requirements of 21 CFR 807.92, the following information provides sufficient detail to understand the basis for a determination of substantial equivalence.

Submitter Name, Address, Contact

Roche Diagnostics 9115 Hague Road, PO. Box 0416 Indianapolis, IN 46250-50416

Contact Person: Kelli Turner

Phone: (317) 521-4515 FAX: (317) 521-2324 Email: kelli.turner@roche.com

Date Prepared: April 28, 2014

# Device Name

Proprietary name: Elecsys CK-MB STAT Immunoassay

Common name: CK-MB STAT Assay

Classification name: Colorimetric method; Cpk or Isoenzymes

Product Code: JHY

Predicate Device: CK-MB STAT Immunoassay, Roche Diagnostics (K132571)

# Special 510(k) Summary, continued

# Establishment Registration

For the CK-MB STAT Assay, the establishment registration number for Roche Diagnostics GmbH in Mannheim, Germany, is 9610126 and for Penzberg, Germany, is 9610529. The establishment registration number for Roche Diagnostics United States is 1823260

# Classification

The FDA has classified the CK-MB STAT as a Class II device.

<table><tr><td rowspan=1 colspan=1>Panel</td><td rowspan=1 colspan=1>ProductCode</td><td rowspan=1 colspan=1>Classification Name</td><td rowspan=1 colspan=1>Regulation Citation</td></tr><tr><td rowspan=1 colspan=1>Clinical Chemistry</td><td rowspan=1 colspan=1>JHY</td><td rowspan=1 colspan=1>Colorimetric Method, CpkOr Isoenzymes</td><td rowspan=1 colspan=1>21 CFR 862.1215</td></tr></table>

# Performance Standards

To date, no performance standards that affect this device have been finalized under Section 514 of the Act.

# Proposed Labeling

Propoed drat labelingsuffcient t describe the device, the intende use, and the directions for use on the cobas e 601 immunoassay analyzer is attached. We believe the draft version of the device labeling presented in Section V contains all of the technical information required per 21 CFR 809.10 for the CK-MB STAT (one-step incubation) Assays.

Continued on next page

# Special 510(k) Summary, continued

# Analyzer Platform

Precision of the CK-MB STAT (one-step incubation) assay was evaluated on one cobas e 601 Immunoassay Analyzers according to CLSI EP5-A2 guidelines. A method comparison between the Elecsys CK-MB STAT (two-step incubation) and CK-MB STAT (one-step incubation) was performed and summarized in Section III, 510(k) summary, Method Comparison.

# Device Description

The CK-MB STAT (one-step incubation) Assay is a sandwich immunoassay with streptavidin microparticles and electrochemiluminescence detection.

Results are determined using a calibration curve that is generated specifically on each instrument by a 2 point calibration and a master curve (5-pointcalibration) provided with the reagent bar code.

The CK-MB STAT (one-step incubation) application is identical to the CKMB STAT (two-step incubation) assay, the only difference being for the CKMB STAT (one-step incubation) application, the sample, reagent 1, reagent 2 and microparticles are added at one time.

Note:Calibrators and controls are packaged and sold separately.

Immunoassay for the in vitro quantitative determination of the MB isoenzyme of creatine kinase in human serum and plasma The electrochemiluminescence immunoassay "ECLIA" is intended for use on the indicated and cobas e immunoassay analyzers.

Continued on next page

# Special 510(k) Summary, continued

# Indications for use

Immunoassay for the in vitro quantitative determination of the MB isoenzyme of creatine kinase in human serum and plasma. Measurements of the MB isoenzyme of creatinine kinase are used as an aid in the diagnosis of myocardial infarction.

The electrochemiluminescence immunoassay "ECLIA" is intended for use on the indicated Elecsys and cobas e immunoassay analyzers.

Special   
conditions for   
use

For prescription use only

Special instrument requirements

The electrochemiluminescence immunoassay "ECLIA" is intended for use on the indicated Elecsys and cobas e immunoassay analyzers.

# Substantial Equivalence

The CK-MB STAT Immunoassay is substantially equivalent to other devices legally marketed in the United States.

CK-MB STAT (one-step incubation) Immunoassays, is equivalent to CK-MB STAT (two-step) Immunoassay, Roche Diagnostics (K132571).

Substantial Equivalence Comparison

The following table compares the CK-MB STAT Immunoassay (onestep incubation) with the predicate device.

# Special 510(k) Summary, continued

Comparison of Assays, Similarities and Differences

Table 1 CK-MB STAT (two-step incubation) vs. CK-MB STAT (one-step incubation)

<table><tr><td rowspan=1 colspan=3>Assay Comparison</td></tr><tr><td rowspan=1 colspan=1>Feature</td><td rowspan=1 colspan=1>Predicate Device: Elecsys CK-MBSTAT (two-step incubation) Assay(K132571)</td><td rowspan=1 colspan=1>CK-MB STAT (one-step incubation)Assay (modified)</td></tr><tr><td rowspan=1 colspan=3>General Assay Features</td></tr><tr><td rowspan=1 colspan=1>IntendedUse/Indicationsfor Use</td><td rowspan=1 colspan=1>Immunoassay for the in vitroquantitative determination of MBisoenzyme of creatine kinase in humanserum and plasma.The electrochemiluminescenceimmunoassay &quot;ECLIA&quot; is intendedfor use on Elecsys and cobas eimmunoassay analyzers.</td><td rowspan=1 colspan=1>Same</td></tr><tr><td rowspan=1 colspan=1>AssayProtocol</td><td rowspan=1 colspan=1>Two step Sandwich assay usingbiotinylated and ruthenium labeledantibodies and streptavidinmicroparticles</td><td rowspan=1 colspan=1>Sandwich assay using biotinylated andruthenium labeled antibodies andstreptavidin microparticles</td></tr><tr><td rowspan=1 colspan=1>DetectionProtocol</td><td rowspan=1 colspan=1>ElectrochemiluminescentImmunoassay</td><td rowspan=1 colspan=1>Same</td></tr><tr><td rowspan=1 colspan=1>Applications</td><td rowspan=1 colspan=1>STAT (9 minute) application</td><td rowspan=1 colspan=1>Same</td></tr></table>

# Special 510(k) Summary, continued

Comparison of Assays—Similarities and Differences, continued

Table 1 continued

<table><tr><td rowspan=1 colspan=7>Assay Comparison</td></tr><tr><td rowspan=1 colspan=1>Feature</td><td rowspan=1 colspan=5>Predicate Device: Elecsys CK-MBSTAT (two-step incubation) Assay(K132571)</td><td rowspan=1 colspan=1>CK-MB STAT (one-step incubation)Assay (modified)</td></tr><tr><td rowspan=1 colspan=7>General Assay Features                        e1</td></tr><tr><td rowspan=1 colspan=1>InstrumentPlatform</td><td rowspan=1 colspan=5>cobas e 411</td><td rowspan=1 colspan=1>Roche cobas e 601</td></tr><tr><td rowspan=1 colspan=1>SampleVolume</td><td rowspan=1 colspan=5>15μL</td><td rowspan=1 colspan=1>Same</td></tr><tr><td rowspan=7 colspan=1>SampleType</td><td rowspan=1 colspan=5>Human serum and plasma treated withK2-EDTA, K3-EDTA, and lithiumheparin and sodium heparin plasma.</td><td rowspan=7 colspan=1>Same</td></tr><tr><td rowspan=1 colspan=1>−</td><td rowspan=1 colspan=1>Specification</td><td rowspan=1 colspan=1>NaHeparinPlasma</td><td rowspan=1 colspan=1>LiHeparinPlasma</td><td rowspan=1 colspan=1>$KEDTAPlasma</td><td rowspan=1 colspan=1>K5EDTAPlasma</td></tr><tr><td rowspan=1 colspan=1>Samplesizenormallyfilledtubes</td><td rowspan=1 colspan=1>at least30</td><td rowspan=1 colspan=1>35</td><td rowspan=1 colspan=1>34</td><td rowspan=1 colspan=1>35</td><td rowspan=1 colspan=1>35</td></tr><tr><td rowspan=1 colspan=1>Slope(BaPa)</td><td rowspan=1 colspan=1>0.91.1</td><td rowspan=1 colspan=1>0.994</td><td rowspan=1 colspan=1>0.996</td><td rowspan=1 colspan=1>1.020</td><td rowspan=1 colspan=1>0.988</td></tr><tr><td rowspan=1 colspan=1>Intercept(BaPa)</td><td rowspan=1 colspan=1>≤+10.15</td><td rowspan=1 colspan=1>0.0010</td><td rowspan=1 colspan=1>0.0045</td><td rowspan=1 colspan=1>-0.0082</td><td rowspan=1 colspan=1>0.0115</td></tr><tr><td rowspan=1 colspan=1>Correlation T</td><td rowspan=1 colspan=1>&gt;0.95</td><td rowspan=1 colspan=1>0.9997</td><td rowspan=1 colspan=1>0.9996</td><td rowspan=1 colspan=1>0.9999</td><td rowspan=1 colspan=1>0.9998</td></tr><tr><td rowspan=1 colspan=1>Relativedeviation forsinglesamplepairs</td><td rowspan=1 colspan=1>+/-20%</td><td rowspan=1 colspan=1>max.deviation14.6 %</td><td rowspan=1 colspan=1>maxdeviation12.0 %</td><td rowspan=1 colspan=1>maxdeviation10.5%</td><td rowspan=1 colspan=1>maxdeviation8.7 %</td></tr><tr><td rowspan=1 colspan=1>Reagents</td><td rowspan=1 colspan=5>Sandwich principle. Total duration ofassay: 9 minutes.1st incubation: 15 μL of sample, abiotinylated monoclonal anti-CK-MBantibody, and a monoclonal CK-MB-specific antibody labeled with aruthenium complex react to form asandwich complex.2nd incubation: After addition ofstreptavidin-coated microparticles, thecomplex becomes bound to the solidphase via interaction of biotin andstreptavidin.</td><td rowspan=1 colspan=1>Sandwich principle. Total duration ofassay: 9 minutesAntigen in the sample (15 μL),a biotinylated monoclonal anti-CK-MB antibody, amonoclonal CK-MB-specificantibody labeled with aruthenium complex andstreptavidin-coatedmicroparticles react to form asandwich complex, which isbound to a solid phase</td></tr></table>

# Special 510(k) Summary, continued

Table 1 continued

Comparison of Assays—Similarities and Differences, continued   

<table><tr><td rowspan=1 colspan=3>Assay Comparison</td></tr><tr><td rowspan=1 colspan=1>Feature</td><td rowspan=1 colspan=1>Predicate Device: Elecsys CK-MBSTAT (two-step incubation) Assay(K132571)</td><td rowspan=1 colspan=1>CK-MB STAT (one-step incubation)Assay (modified)</td></tr><tr><td rowspan=1 colspan=3>General Assay Features</td></tr><tr><td rowspan=1 colspan=1>Calibrator</td><td rowspan=1 colspan=1>CK-MB STAT CalSet</td><td rowspan=1 colspan=1>Same</td></tr><tr><td rowspan=1 colspan=1>CalibrationInterval</td><td rowspan=1 colspan=1>Calibration must be performed onceper reagent lot using fresh reagent(i.e. not more than 24 hours since thereagent kit was registered on theanalyzer). Renewed calibration isrecommended as follows:•  After 12 weeks when usingthe same reagent lot.After 7 days (when using thesame reagent kit on theanalyzer).As required: e.g. qualitycontrol findings outside thespecified limits</td><td rowspan=1 colspan=1>Same</td></tr><tr><td rowspan=1 colspan=1>Controls</td><td rowspan=1 colspan=1>Elecsys PreciControl Cardiac II</td><td rowspan=1 colspan=1>Same</td></tr></table>

# Special 510(k) Summary, continued

Comparison of Assays—Similarities and Differences, continued

Table 1 continued

<table><tr><td rowspan=1 colspan=3>Assay Comparison</td></tr><tr><td rowspan=1 colspan=1>Feature</td><td rowspan=1 colspan=1>Predicate Device: Elecsys CK-MBSTAT (two-step incubation) Assay(K132571)</td><td rowspan=1 colspan=1>CK-MB STAT (one-stepincubation) Assay (modified)</td></tr><tr><td rowspan=1 colspan=3>General assay features</td></tr><tr><td rowspan=1 colspan=1>Traceability /Standardization</td><td rowspan=1 colspan=1>The CK-MB STAT assay is traceableto the Abbott IMx CK-MB assay andlinearized using human recombinantCK-MB from Seradyn</td><td rowspan=1 colspan=1>Same</td></tr><tr><td rowspan=1 colspan=1>Reagent Stability</td><td rowspan=1 colspan=1>Unopened:2-8°C - Up to the stated expirationdateOpened 2-8°C - 12 weeksOn Analyzers - 8 weeks</td><td rowspan=1 colspan=1>Same</td></tr><tr><td rowspan=1 colspan=1>Linearitydetermined withserum samples.</td><td rowspan=1 colspan=1>Series 1: y=0.9421 -0.0579Series 2: y=0.9348-0.116Series 3: y=0.942-0.0964</td><td rowspan=1 colspan=1>Series 1: y=0.9571 -0.1267(range: 0.27 to 563 ng/mL)Series 2: y=0.9499-0.0957(range: 0.13 to 548 ng/mL)Series 3: y=0.9576-0.1188(range: 0.16 to 328 ng/mL)Note: linearity was established at ±1 1.3% within the stated measuringrange.</td></tr></table>

# Special 510(k) Summary, continued

Table 1 continued

Comparison of Assays—Similarities and Differences, continued   

<table><tr><td rowspan=1 colspan=3>Assay Comparison</td></tr><tr><td rowspan=1 colspan=1>Feature</td><td rowspan=1 colspan=1>Predicate Device: Elecsys CK-MBSTAT (two-step incubation) Assay(K132571)</td><td rowspan=1 colspan=1>CK-MB STAT (one-stepincubation) Assay (modified)</td></tr><tr><td rowspan=1 colspan=3>Labeled Performance Characteristics                   :</td></tr><tr><td rowspan=1 colspan=1>MeasuringRange</td><td rowspan=1 colspan=1>1-300 ng/mL</td><td rowspan=1 colspan=1>Same</td></tr><tr><td rowspan=1 colspan=1>Precision</td><td rowspan=1 colspan=1>cobas e 411:Within-run (will be labeled Repcatability)1.2% CV@    5.46 ng/mL1.3% CV @    29.5 ng/mL1.3% CV @    93.5 ng/mL1.5% CV @    301 ng/mL1.3% CVPCI@    4.44 ng/mL1.4% CVPC257.9 ng/mLTotal (will be labeled Intermediate)2.5% CV @     5.46 ng/mL4.2% CV @    29.5 ng/mL4.1% CV @    93.5 ng/mL3.3% CV @     301 ng/mL2.6% CVPCI@     4.44 ng/mL3.0% CVPC2@     57.9 ng/mL</td><td rowspan=1 colspan=1>cobas e 601:Within-run (will be labeled Repeatability)1.1% CV @    5.34 ng/mL1.1% CV @    27.3 ng/mL1.1% CV @    89.2 ng/mL0.8% CV @    283 ng/mL1.2% CVPCI@    4.27 ng/mL0.9% CV    54.3 ng/mLTotal (will bc labcled Intermediate)1.4% CV @    5.34 ng/mL3.2% CV @    27.3 ng/mL2.5% CV @    89.2 ng/mL2.2% CV @    283 ng/mL1.4% CVPCI@     4.27 ng/mL1.3% CVPC2@     54.3 ng/mL</td></tr><tr><td rowspan=1 colspan=1>AnalyticalSensitivity</td><td rowspan=1 colspan=1>Limit of Blank (LoB): = 0.1 ng/mlLimit of Detection (LoD): = 0.3 ng/mlLimit of Quantitation (LoQ): = 1 ng/mlEstablished according to CLSI EP17- A</td><td rowspan=1 colspan=1>Same</td></tr></table>

PC1 $=$ PreciControl Cardiac 1 $\mathbf { P C 2 = }$ PreciControl Cardiac 2

# Special 510(k) Summary, continued

# Comparison of Assays—Similarities and Differences, continued

Table 1 continued   

<table><tr><td rowspan=1 colspan=8>Assay Comparison</td></tr><tr><td rowspan=1 colspan=1>Feature</td><td rowspan=1 colspan=6>Predicate Device: Elecsys CK-MBSTAT (two-step incubation) Assay(K132571)</td><td rowspan=1 colspan=1>CK-MB STAT (one-step incubation)Assay (modified)</td></tr><tr><td rowspan=1 colspan=8>Labeled Performance Characteristics</td></tr><tr><td rowspan=3 colspan=1>AnalyticalSpecificity</td><td></td><td rowspan=1 colspan=3>Analyte</td><td rowspan=1 colspan=1>Reactivity</td><td></td><td rowspan=3 colspan=1>Same</td></tr><tr><td></td><td rowspan=1 colspan=3>CK-MM</td><td rowspan=1 colspan=1>None</td><td></td></tr><tr><td></td><td rowspan=1 colspan=3>CK-BB</td><td rowspan=1 colspan=1>0.10%</td><td></td></tr><tr><td rowspan=1 colspan=1>Hook Effect</td><td rowspan=1 colspan=6>There is no high-dose hook effect atCK-MB concentrations up to 5000ng/mL</td><td rowspan=1 colspan=1>Same</td></tr><tr><td rowspan=11 colspan=1>Limitations</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td rowspan=1 colspan=2>Interferenttested</td><td rowspan=1 colspan=1>Nointerferenceup to</td><td></td><td></td><td></td><td></td></tr><tr><td rowspan=1 colspan=2>Intralipid(Lipemia)</td><td rowspan=1 colspan=1>2000 mg/dL</td><td></td><td></td><td></td><td></td></tr><tr><td rowspan=1 colspan=2>Biotin</td><td rowspan=1 colspan=1>50 ng/mL</td><td></td><td></td><td></td><td></td></tr><tr><td rowspan=1 colspan=2>Bilirubin</td><td rowspan=1 colspan=1>40 mg/dL</td><td></td><td></td><td></td><td></td></tr><tr><td rowspan=1 colspan=2>Hemoglobin</td><td rowspan=1 colspan=1>1000 mg/dL</td><td></td><td></td><td></td><td></td></tr><tr><td rowspan=1 colspan=2>Rheumatoid Factor</td><td rowspan=1 colspan=1>1700 1U/mL</td><td></td><td></td><td></td><td></td></tr><tr><td rowspan=1 colspan=2>Human Serumalbumin</td><td rowspan=1 colspan=1>14 g/dL</td><td></td><td></td><td></td><td></td></tr><tr><td rowspan=1 colspan=2>Human lgG</td><td rowspan=1 colspan=1>7 g/dL</td><td></td><td></td><td></td><td></td></tr><tr><td rowspan=1 colspan=2>Human IgM</td><td rowspan=1 colspan=1>1 g/dL</td><td></td><td></td><td></td><td></td></tr><tr><td rowspan=1 colspan=2>Human IgA</td><td rowspan=1 colspan=1>1.6 g/dL</td><td></td><td></td><td></td><td></td></tr></table>

# Special 510(k) Summary, continued

<table><tr><td rowspan=1 colspan=5>Assay Comparison</td></tr><tr><td rowspan=1 colspan=1>Feature</td><td rowspan=1 colspan=3>Predicate Device: Elecsys CK-MBSTAT (two-step incubation) Assay(K132571)</td><td rowspan=1 colspan=1>CK-MB STAT (one-step incubation)Assay (modified)</td></tr><tr><td rowspan=1 colspan=5>Labeled Performance Characteristics</td></tr><tr><td rowspan=20 colspan=1>Limitations,continued</td><td></td><td></td><td></td><td></td></tr><tr><td rowspan=1 colspan=1>Drug</td><td rowspan=1 colspan=1>Concentration</td><td></td><td></td></tr><tr><td rowspan=1 colspan=1>Acctylcysteine</td><td rowspan=1 colspan=1>150 mg/L</td><td></td><td></td></tr><tr><td rowspan=1 colspan=1>Ampicillin-Na</td><td rowspan=1 colspan=1>1000 mg/L</td><td></td><td></td></tr><tr><td rowspan=1 colspan=1>Ascorbic acid</td><td rowspan=1 colspan=1>300 mg/L</td><td></td><td></td></tr><tr><td rowspan=1 colspan=1>Ca- Dobesilate</td><td rowspan=1 colspan=1>200 mg/L</td><td></td><td></td></tr><tr><td rowspan=1 colspan=1>Cyclosporine</td><td rowspan=1 colspan=1>5 mg/L</td><td></td><td></td></tr><tr><td rowspan=1 colspan=1>Cefoxitin</td><td rowspan=1 colspan=1>2500 mg/L</td><td></td><td></td></tr><tr><td rowspan=1 colspan=1>Hcparin</td><td rowspan=1 colspan=1>5000 U</td><td></td><td></td></tr><tr><td rowspan=1 colspan=1>Intralipid</td><td rowspan=1 colspan=1>10000 mg/L</td><td></td><td></td></tr><tr><td rowspan=1 colspan=1>Lcvodopa</td><td rowspan=1 colspan=1>20 mg/L</td><td></td><td></td></tr><tr><td rowspan=1 colspan=1>Methyldopa + 1.520 mg/LH2O</td><td rowspan=1 colspan=1></td><td></td><td></td></tr><tr><td rowspan=1 colspan=1>Metronidazole</td><td rowspan=1 colspan=1>200 mg/L</td><td></td><td></td></tr><tr><td rowspan=1 colspan=1>Phenybutazone</td><td rowspan=1 colspan=1>400 mg/L</td><td></td><td></td></tr><tr><td rowspan=1 colspan=1>Doxycycline</td><td rowspan=1 colspan=1>50 mg/L</td><td></td><td></td></tr><tr><td rowspan=1 colspan=1>AcetylsalicylicAcid</td><td rowspan=1 colspan=1>1000 mg/L</td><td></td><td></td></tr><tr><td rowspan=1 colspan=1>Rifampicin</td><td rowspan=1 colspan=1>60 mg/L</td><td></td><td></td></tr><tr><td rowspan=1 colspan=1>Acetaminophen</td><td rowspan=1 colspan=1>200 mg/L</td><td></td><td></td></tr><tr><td rowspan=1 colspan=1>Ibuprofen</td><td rowspan=1 colspan=1>500 mg/L</td><td></td><td></td></tr><tr><td rowspan=1 colspan=1>Theophylline</td><td rowspan=1 colspan=1>100 mg/L</td><td></td><td></td></tr></table>

# Special 510(k) Summary, continued

<table><tr><td rowspan=1 colspan=6>Assay Comparison</td></tr><tr><td rowspan=1 colspan=1>Feature</td><td rowspan=1 colspan=4>Predicate Device: Elecsys CK-MBSTAT (two-step incubation) Assay(K132571)</td><td rowspan=1 colspan=1>CK-MB STAT (one-step incubation)Assay (modified)</td></tr><tr><td rowspan=1 colspan=6>Labeled Performance Characteristics</td></tr><tr><td></td><td></td><td rowspan=1 colspan=1>Special Drug</td><td rowspan=1 colspan=1>Concentration</td><td></td><td></td></tr><tr><td></td><td></td><td rowspan=1 colspan=1>Carvedilol</td><td rowspan=1 colspan=1>50 mg/l.</td><td></td><td></td></tr><tr><td></td><td></td><td rowspan=1 colspan=1>Propanolol</td><td rowspan=1 colspan=1>160 mg/l</td><td></td><td></td></tr><tr><td></td><td></td><td rowspan=1 colspan=1>Marcumar</td><td rowspan=1 colspan=1>9 mg/L</td><td></td><td></td></tr><tr><td></td><td></td><td rowspan=1 colspan=1>Reteplase</td><td rowspan=1 colspan=1>20 U/L</td><td></td><td></td></tr><tr><td></td><td></td><td rowspan=1 colspan=1>Suprarenin(Adrenalin)</td><td rowspan=1 colspan=1>3 mg/L</td><td></td><td></td></tr><tr><td></td><td></td><td rowspan=1 colspan=1>Methylprednislon</td><td rowspan=1 colspan=1>40 mg/l</td><td></td><td></td></tr><tr><td></td><td></td><td rowspan=1 colspan=1>Verapamil</td><td rowspan=1 colspan=1>480 mg/l</td><td></td><td></td></tr><tr><td></td><td></td><td rowspan=1 colspan=1>Lidocain</td><td rowspan=1 colspan=1>500 mg/L</td><td></td><td></td></tr><tr><td></td><td></td><td rowspan=1 colspan=1>Enalapril</td><td rowspan=1 colspan=1>40 mg/L</td><td></td><td></td></tr><tr><td></td><td></td><td rowspan=1 colspan=1>Captopril</td><td rowspan=1 colspan=1>150 mg/L</td><td></td><td></td></tr><tr><td></td><td></td><td rowspan=1 colspan=1>Lisinopril</td><td rowspan=1 colspan=1>40 mg/l</td><td></td><td></td></tr><tr><td></td><td></td><td rowspan=1 colspan=1>Aldactone(Spironolacton)</td><td rowspan=1 colspan=1>400 mg/l.</td><td></td><td></td></tr><tr><td></td><td></td><td rowspan=1 colspan=1>Torasemid</td><td rowspan=1 colspan=1>5 mg/L</td><td></td><td></td></tr><tr><td></td><td></td><td rowspan=1 colspan=1>Insulin</td><td rowspan=1 colspan=1>150 I.U.</td><td></td><td></td></tr><tr><td></td><td></td><td rowspan=1 colspan=1>Tolbutamid</td><td rowspan=1 colspan=1>10.5 mg/l.</td><td></td><td></td></tr><tr><td></td><td></td><td rowspan=1 colspan=1>Gentamycin</td><td rowspan=1 colspan=1>420 mg/L</td><td></td><td></td></tr><tr><td></td><td></td><td rowspan=1 colspan=1>Lovostatin</td><td rowspan=1 colspan=1>80 mg/L</td><td></td><td></td></tr><tr><td></td><td></td><td rowspan=1 colspan=1>Pravastatin</td><td rowspan=1 colspan=1>8 mg/L</td><td></td><td></td></tr><tr><td></td><td></td><td rowspan=1 colspan=1>Simvastin</td><td rowspan=1 colspan=1>80 mg/L</td><td></td><td></td></tr><tr><td></td><td></td><td rowspan=1 colspan=1>Bisprolol</td><td rowspan=1 colspan=1>20 mg/L</td><td></td><td></td></tr><tr><td></td><td></td><td rowspan=1 colspan=1>Nitrolingual(Glyceroltrinitrat)</td><td rowspan=1 colspan=1>1.6 mg/L</td><td></td><td></td></tr><tr><td></td><td></td><td rowspan=1 colspan=1>Heparin</td><td rowspan=1 colspan=1>7500 I.U.</td><td></td><td></td></tr><tr><td></td><td></td><td rowspan=1 colspan=1>Metropolol</td><td rowspan=1 colspan=1>200 mg/L</td><td></td><td></td></tr><tr><td></td><td></td><td rowspan=1 colspan=1>Molsidomin</td><td rowspan=1 colspan=1>16 mg/L</td><td></td><td></td></tr><tr><td></td><td></td><td rowspan=1 colspan=1>Nicardipin</td><td rowspan=1 colspan=1>160 mg/L</td><td></td><td></td></tr><tr><td></td><td></td><td rowspan=1 colspan=1>Nifedipin</td><td rowspan=1 colspan=1>60 mg/L</td><td></td><td></td></tr><tr><td></td><td></td><td rowspan=1 colspan=1>Propafenon</td><td rowspan=1 colspan=1>900 mg/L</td><td></td><td></td></tr><tr><td></td><td></td><td rowspan=1 colspan=1>Solatol</td><td rowspan=1 colspan=1>480 mg/L</td><td></td><td></td></tr><tr><td></td><td></td><td rowspan=1 colspan=1>Streptokkinase</td><td rowspan=1 colspan=1>10 000 000 I.U.</td><td></td><td></td></tr><tr><td></td><td></td><td rowspan=1 colspan=1>Urokinase</td><td rowspan=1 colspan=1>4200000 mg/l.</td><td></td><td></td></tr><tr><td></td><td></td><td rowspan=1 colspan=1>Digoregen (Digoxin)</td><td rowspan=1 colspan=1>0.5 mg/L</td><td></td><td></td></tr><tr><td></td><td></td><td rowspan=1 colspan=1>Digimerck minor(Digitoxin)</td><td rowspan=1 colspan=1>0.21 mg/L</td><td></td><td></td></tr><tr><td></td><td></td><td rowspan=1 colspan=1>Clopidroge!</td><td rowspan=1 colspan=1>300 mg/L</td><td></td><td></td></tr></table>

# Special ${ \bar { \bf 5 } } 1 0 ( { \bf k } )$ Summary, continued

<table><tr><td rowspan=1 colspan=3>Assay Comparison</td></tr><tr><td rowspan=1 colspan=1>Feature</td><td rowspan=1 colspan=1>Predicate Device: Elecsys CK-MBSTAT (two-step incubation) Assay(K132571)</td><td rowspan=1 colspan=1>CK-MB STAT (one-step incubation)Assay (modified)</td></tr><tr><td rowspan=1 colspan=3>Labeled Performance Characteristics</td></tr><tr><td rowspan=1 colspan=1>Limitations,continued</td><td rowspan=1 colspan=1>In rare cases, interference due toextremely high titers of antibodies toanalyte-specific antibodies, streptavidinor ruthenium can occur. These effectsare minimized by suitable test design.For diagnostic purposes, the results shouldalways be assessed in conjunction with thepatient&#x27;s medical history, clinicalexamination and other findingsThese limitations wcre established bytesting performed with one human scrumsample containing low levels of CK-MBand one human serum sample containinghigh levels of CK-MB.</td><td rowspan=1 colspan=1>Same</td></tr></table>

# Special ${ \bf 5 1 0 ( k ) }$ Summary, continued

Comparison of Assays—Similarities and Differences, continued

<table><tr><td rowspan=1 colspan=8>Immunoassay Comparison</td></tr><tr><td rowspan=1 colspan=1>Feature</td><td rowspan=1 colspan=6>Predicate Device: Elecsys CK-MBSTAT (two-step incubation) Assay(K132571)</td><td rowspan=1 colspan=1>CK-MB STAT (one-stepincubation) Assay (modified)</td></tr><tr><td rowspan=1 colspan=8>Labeled Performance Characteristics</td></tr><tr><td rowspan=6 colspan=1>ClinicalStudy/referencerange</td><td></td><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1>Gender</td><td rowspan=1 colspan=2>(N)</td><td rowspan=1 colspan=1>99thpercentile(ng/mL)</td><td rowspan=6 colspan=1>Same</td></tr><tr><td></td><td rowspan=2 colspan=1>AllSubjects</td><td rowspan=1 colspan=1>Female</td><td rowspan=1 colspan=2>523</td><td rowspan=1 colspan=1>5.34</td></tr><tr><td></td><td rowspan=1 colspan=1>Male</td><td rowspan=1 colspan=2>568</td><td rowspan=1 colspan=1>10.36</td></tr><tr><td></td><td rowspan=2 colspan=1>Subjectswith noSelf-reportedriskfactors</td><td rowspan=1 colspan=1>Female</td><td rowspan=1 colspan=2>120</td><td rowspan=1 colspan=1>4.30</td></tr><tr><td></td><td rowspan=1 colspan=1>Male</td><td rowspan=1 colspan=2>102</td><td rowspan=1 colspan=1>7.70</td></tr><tr><td rowspan=1 colspan=6>Subjects represented &quot;apparently hearthealthy&quot; population with exclusion ofsubjects with known poor cardiac healthor known peripheral vascular diseaseonly.</td></tr><tr><td rowspan=1 colspan=8>Additional Performance Characteristics</td></tr><tr><td rowspan=7 colspan=1>MethodComparisonElecsys CK-MBSTAT on cobase 411(two-stepincubation) vs.Elecsys CK-MBSTAT on cobase 601 (one-stepincubation)</td><td rowspan=7 colspan=7>n = 115                     Passing/BablokMin = 1.47 ng/mlMax = 269 ng/mlSlope                                0.976Intercept                            0.053Tau                                  0.991</td></tr><tr><td rowspan=1 colspan=3>n = 115</td></tr><tr><td rowspan=1 colspan=3>Min = 1.47 ng/ml</td></tr><tr><td rowspan=1 colspan=3>Max = 269 ng/ml</td></tr><tr><td rowspan=1 colspan=3>Slope</td><td rowspan=1 colspan=2>0.976</td></tr><tr><td rowspan=1 colspan=3>Intercept</td><td rowspan=1 colspan=2>0.053</td></tr><tr><td rowspan=1 colspan=3>Tau</td><td rowspan=1 colspan=2>0.991</td></tr></table>

# Special 510(k) Summary, continued

Standard/ Guidance Document Reference

In addition to FDA guidance regarding $5 1 0 ( \mathbf { k } )$ submissions, the following standards were used for the performance studies.

Evaluation of Precision Performance of Quantitative Measurement Methods; Approved Guideline  Second Edition. CLSI document EP5-A2, Volume 24, No. 25, August 2004.

Protocols for Determination of Limits of Detection and Limits of Quantitation; Approved Guideline. CLSI document EP 17-A, Volume 24, No. 34, October 2004.

Evaluation of the Linearity of Quantitative Measurement Procedures: A Statistical Approach; Approved Guideline. CLSI document EP6-A, Volume 23, No. 16, April 2003.

Data for CK-MB STAT (one-step incubation) is on file at Roche Diagnostics.

# Conclusion

The submitted information in this premarket notification supports a substantial equivalence decision. The differences between predicate and candidate do not impact the indications for use or technological characteristics.

May 8, 2014

ROCHE DIAGNOSTICS   
KELLI TURNER   
REGULATORY AFFAIRS PRINCIPLE   
91 15 HAGUE ROAD   
INDIANAPOLIS IN 46250

Re: K140404 Trade/Device Name: Elecsys CK-MB STAT Immunoassay Regulation Number: 21 CFR 862.1215 Regulation Nae: Creatine phosphokinas/creatine knase  isonzymes test systm Regulatory Class: I1 Product Code: JHY Dated: April 07, 2014 Received: April 08, 2014

Dear Ms. Turner:

We have reviewed your Section 5 10(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28. 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassifed in accordance with he provisions of the Federal Food. Drug. and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device. subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, listing of devices. good manufacturing practice, labeling, and prohibitions against misbranding and adulteration. Please note: CDRH docs not evaluate information related to contract liability warranties. We remind you, however, that device labcling must be truthful and not misleading.

If your device is classified (see above) into cither class II (Special Controls) or class  (PMA). it may be subject to additional controls. Existing major regulations affecting your device can be found in the Code of Eederal Regulations. Title . Parts 800 to 89. In addition. FDA may publish further announceiments concerning your device in the Federal Register.

Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination thal your devicc complies with other requirements of the Act or any Federal statutes and regulations administcred by other Federal agencies. You must comply with all the Act's requirements, including. but not limited to: registration and listing (21 CFR Part 807): labeling (21 CFR Parts 801 and 809): medical device reporting (reporing of medical device-related adverse events) (21 CFR 803): good manufacturing practice requirements as set forth in the quality systems (QS) regulation (21 CFR Part 820): and if applicable, the electronic product radiation control provisions (Sections 531-542 of thc Act); 21 CFR 1000- 1050.

If you desire specific advice for your device on our labeling regulations (21 CFR Parts 801 and 809), please contact the Division of Industry and Consumer Education at its toll-free number (800) 638 2041 or (301) 796-7100 or al its Intemet address   
http://www.fda.gov/MedicalDcvices/ResourcesforYou/Industry/default.htm. Also. please notc the regulation entitled. "Misbranding by reference to premarket notification" (21CFR Part 807.97). For questions regarding the reporting of adversc events under the MDR regulation (21 CFR Part 803). plcase go to   
http://www.fda.gov/MedicalDevices/Safety/ReportaProblem/default.htm for the CDRHl's Office of Surveillance and Biometrics/Division of Postmarket Surveillance.

You may obtain other general information on your responsibilities under the Act from the Division of Industry and Consumer Education at its toll-free number (800) 638-2041 or (301) 796-7100 or at its Internet address http:/www.fda.gov/MedicalDevices/ResourcesforYou/Industrv/default.hum.

Sincerely yours.

# Courtney H. Lias -S

Courtney H. Lias. Ph.D.   
Director   
Division of Chemistry and Toxicology Devices Office of In Vitro Diagnostics   
and Radiological Health   
Center for Devices and Radiological Health

Device Name Elecsys CK-MB STAT Immunoassay

The elecohemilueccassy "ECLsinten usn Elcys nd cob ssyn.

<table><tr><td>Type of Use (Select ne or both, as applicable) Prescription Use (Part 21 CFR 801 Subpar D) Over-The-Counter Use (21 CFR 801 Subpar C)</td></tr><tr><td>PLEASE DO NOT WRITE BELOW THIS LINE - CONTINUE ON A SEPARATE PAGE IF NEEDED.</td></tr><tr><td>FOR FDA USE ONLY</td></tr><tr><td>Concurrence of Center for Devices and Radiological Health (CDRH) (Signature) Ruth A. Chesler -S</td></tr><tr><td></td></tr></table>